Literature DB >> 34666994

Patterns of Carbon-Bound Exogenous Compounds in Patients with Lung Cancer and Association with Disease Pathophysiology.

Thomas Kunzke1, Verena M Prade1, Achim Buck1, Na Sun1, Annette Feuchtinger1, Marco Matzka1, Isis E Fernandez2,3, Wim Wuyts4, Maximilian Ackermann5,6, Danny Jonigk7,8, Michaela Aichler1, Ralph A Schmid9, Oliver Eickelberg10, Sabina Berezowska11,12, Axel Walch13.   

Abstract

Asymptomatic anthracosis is the accumulation of black carbon particles in adult human lungs. It is a common occurrence, but the pathophysiologic significance of anthracosis is debatable. Using in situ high mass resolution matrix-assisted laser desorption/ionization (MALDI) fourier-transform ion cyclotron resonance (FT-ICR) mass spectrometry imaging analysis, we discovered noxious carbon-bound exogenous compounds, such as polycyclic aromatic hydrocarbons (PAH), tobacco-specific nitrosamines, or aromatic amines, in a series of 330 patients with lung cancer in highly variable and unique patterns. The characteristic nature of carbon-bound exogenous compounds had a strong association with patient outcome, tumor progression, the tumor immune microenvironment, programmed death-ligand 1 (PD-L1) expression, and DNA damage. Spatial correlation network analyses revealed substantial differences in the metabolome of tumor cells compared with tumor stroma depending on carbon-bound exogenous compounds. Overall, the bioactive pool of exogenous compounds is associated with several changes in lung cancer pathophysiology and correlates with patient outcome. Given the high prevalence of anthracosis in the lungs of adult humans, future work should investigate the role of carbon-bound exogenous compounds in lung carcinogenesis and lung cancer therapy. SIGNIFICANCE: This study identifies a bioactive pool of carbon-bound exogenous compounds in patient tissues associated with several tumor biological features, contributing to an improved understanding of drivers of lung cancer pathophysiology. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34666994     DOI: 10.1158/0008-5472.CAN-21-1175

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

Review 1.  Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies.

Authors:  Peter E Hall; Peter Schmid
Journal:  Breast Cancer Res Treat       Date:  2022-03-02       Impact factor: 4.872

2.  Spatial metabolomics for evaluating response to neoadjuvant therapy in non-small cell lung cancer patients.

Authors:  Jian Shen; Na Sun; Philipp Zens; Thomas Kunzke; Achim Buck; Verena M Prade; Jun Wang; Qian Wang; Ronggui Hu; Annette Feuchtinger; Sabina Berezowska; Axel Walch
Journal:  Cancer Commun (Lond)       Date:  2022-05-20

3.  MALDI Mass Spectrometry Imaging-Prognostic Pathways and Metabolites for Renal Cell Carcinomas.

Authors:  Franziska Erlmeier; Na Sun; Jian Shen; Annette Feuchtinger; Achim Buck; Verena M Prade; Thomas Kunzke; Peter Schraml; Holger Moch; Michael Autenrieth; Wilko Weichert; Arndt Hartmann; Axel Walch
Journal:  Cancers (Basel)       Date:  2022-03-30       Impact factor: 6.639

4.  Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma.

Authors:  Na Sun; Marija Trajkovic-Arsic; Fengxia Li; Yin Wu; Corinna Münch; Thomas Kunzke; Annette Feuchtinger; Katja Steiger; Anna Melissa Schlitter; Wilko Weichert; Irene Esposito; Jens T Siveke; Axel Walch
Journal:  EJNMMI Res       Date:  2021-12-01       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.